Retreatment with talquetamab and pomalidomide in triple‐class– BCMA – GPRC5D refractory myeloma

Documenti analoghi

• Risk‐adapted treatment in multiple myeloma: Does more make it merrier?
  di: Saurabh Zanwar, et al.
  Pubblicazione: (2024)
• Sequence not salvage
  di: Douglas W. Sborov, et al.
  Pubblicazione: (2024)
• Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on GPRC5D ‐directed therapies in relapsed multiple myeloma
  di: Laura Joiner, et al.
  Pubblicazione: (2025)
• Metformin augments GPRC5D in multiple myeloma and enhances the efficacy of GPRC5D‐CAR T cells
  di: Xiaoli Hu, et al.
  Pubblicazione: (2024)
• Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
  di: M. R. Seefat, et al.
  Pubblicazione: (2025)